Form 4: Heron Therapeutics Director Granted 53,960 RSUs
Insider Transaction Report
Heron Therapeutics Director Craig A. Johnson was granted 53,960 restricted stock units, vesting in full on January 30, 2027.
Summary
- Craig A. Johnson, a Director of Heron Therapeutics, Inc. (HRTX), acquired 53,960 shares of common stock.
- The acquisition occurred on January 30, 2026, at a price of $0 per share.
- These shares were granted as restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of common stock.
- The restricted stock units are scheduled to vest in full on January 30, 2027.
- Following this transaction, Mr. Johnson beneficially owns 53,960 shares of common stock directly.
- A Power of Attorney, dated September 4, 2025, designates Kathryn Lester and Melissa Jarel as attorneys-in-fact for Mr. Johnson to handle SEC filings.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive event, primarily due to the alignment of director interests with shareholder value through equity compensation. It is a routine compensation action rather than a significant operational or financial development.
Positives
- The grant of restricted stock units to Director Craig A. Johnson aligns his interests with those of shareholders, as the value of his compensation is tied to the company's stock performance.
- The vesting schedule provides an incentive for long-term commitment and performance from the director.
Future Outlook
The 53,960 restricted stock units granted to Director Craig A. Johnson are scheduled to vest in full on January 30, 2027, indicating a future milestone for his compensation.
Industry Context
StockSavvy.ai notes that the grant of restricted stock units is a common and standard practice in executive and director compensation across the biotechnology and pharmaceutical industries. This method is widely used to align the interests of company leadership with long-term shareholder value creation.
Comparison to Industry Standards
- The use of restricted stock units (RSUs) as a compensation mechanism for directors is a standard practice, comparable to compensation structures observed at peer companies in the biotechnology sector such as BioMarin Pharmaceutical Inc. (BMRN) or Acadia Pharmaceuticals Inc. (ACAD).
- The vesting schedule, typically over one to several years, is also consistent with industry norms designed to promote long-term retention and performance alignment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Administrative Setup | Craig Johnson executed a Power of Attorney on September 4, 2025, appointing Kathryn Lester and Melissa Jarel as attorneys-in-fact. This grants them full authority to prepare, execute, and file SEC forms (including Forms 3, 4, 5, Schedules 13D, 13G, and Forms 144) on his behalf, manage his EDGAR account, and obtain transaction information. | 09/04/2025 | This administrative change streamlines the director's compliance with SEC reporting requirements, ensuring timely and accurate filings for insider transactions. It does not alter the company's core governance structure but enhances efficiency in regulatory adherence. |
Stakeholder Impact
- Shareholders: The RSU grant aligns the director's financial incentives with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decision-making.
Next Steps
- The 53,960 restricted stock units will vest in full on January 30, 2027, at which point they will convert into shares of common stock.
Key Dates
| Date | Description |
|---|---|
| 09/04/2025 | Date Power of Attorney was executed by Craig Johnson. |
| 01/30/2026 | Date of RSU grant transaction for 53,960 shares. |
| 02/03/2026 | Date the Form 4 was signed by the attorney-in-fact. |
| 01/30/2027 | Date when the 53,960 restricted stock units will vest in full. |
Recommendation
holdThe RSU grant to a director is a standard compensation practice and does not provide new fundamental information that would significantly alter the investment thesis for Heron Therapeutics. While it fosters alignment, it is not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing.
Keywords
Heron Therapeutics, HRTX, Craig Johnson, Restricted Stock Units, RSU Grant, Director Compensation, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.